Cargando…
A Randomized, Double‐Blind, Placebo‐ and Positive‐Controlled, 4‐Period Crossover Study of the Effects of Solriamfetol on QTcF Intervals in Healthy Participants
Solriamfetol, a dopamine and norepinephrine reuptake inhibitor, is approved (United States and European Union; Sunosi) to treat excessive daytime sleepiness associated with narcolepsy (75‐150 mg/day) or obstructive sleep apnea (37.5‐150 mg/day). A thorough QT/QTc study assessed solriamfetol effects...
Autores principales: | Zomorodi, Katie, Chen, Dan, Lee, Lawrence, Swearingen, Dennis, Carter, Lawrence P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8048583/ https://www.ncbi.nlm.nih.gov/pubmed/32935460 http://dx.doi.org/10.1002/cpdd.867 |
Ejemplares similares
-
Effects of solriamfetol on on‐the‐road driving in participants with narcolepsy: A randomised crossover trial
por: Vinckenbosch, Frederick, et al.
Publicado: (2022) -
Single‐Dose Pharmacokinetics and Safety of Solriamfetol in Participants With Normal or Impaired Renal Function and With End‐Stage Renal Disease Requiring Hemodialysis
por: Zomorodi, Katie, et al.
Publicado: (2019) -
A randomized, double-blind, placebo-controlled, crossover study to
evaluate the human abuse liability of solriamfetol, a selective dopamine and
norepinephrine reuptake inhibitor
por: Carter, Lawrence P, et al.
Publicado: (2018) -
Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Omadacycline on QT/QTc Intervals in Healthy Subjects
por: Darpo, Borje, et al.
Publicado: (2019) -
Randomized, Double-Blind, Placebo- and Positive-Controlled Crossover Study of the Effects of Tebipenem Pivoxil Hydrobromide on QT/QTc Intervals in Healthy Subjects
por: Gupta, Vipul K., et al.
Publicado: (2021)